Search

Fragestellung: In der Schweiz sind nur noch 12 Zentren zur Versorgung Schwerverletzter zugelassen. Wir interessierten uns an einem dieser Traumazentren, wie hoch je der Anteil primär vom Unfallort versus sekundär über ein anderes Spital zugewiesener Schwerverletzter ist sowie für[zum vollständigen Text gelangen Sie über die oben angegebene URL], Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2019)

Fragestellung: Eigene Untersuchungen konnten zeigen, dass die vom «American College of Surgeons» empfohlenen Grenzwerte für eine adäquate Über- und Untertriage von schwer verletzten Patienten mit einer Modifikation der für das TraumaNetzwerk® DGU empfohlenen Schockraumkriterien[zum vollständigen Text gelangen Sie über die oben angegebene URL], Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2019)

Zielsetzung: Das Projekt hatte zum Ziel, mit besonderem Fokus auf vulnerable ältere Patienten das chirurgische Austrittsmanagement in einem Zentrumsspital unter Einsatz entsprechender „assessment“-Instrumente und Umsetzung standardisierter Abläufen zu optimieren. Der Erfolg des[zum vollständigen Text gelangen Sie über die oben angegebene URL], 4. Alterstraumatologie Kongress 2018

When a person, due to brain injury or other disease, suffers in his or her ability to speak, it becomes inherently cumbersome to share needs, emotions, and experiences through personal stories and social interaction. We report on our early design exploration to share everyday experiences by photos for people having expressive aphasia. We also introduce the concept of a multimodal narrative template to help persons with aphasia to reconstruct their experiences and hence promote face-to-face communication and social interaction from everyday activities.

Einleitung: Die aggressive chirurgische Behandlung lokal fortgeschrittener PCa hat weite Akzeptanz gefunden. Die Relevanz einer standardisierten extendierten LA und deren Rolle in der Detektion von Lymphknoten (LK)-Metastasen wurden in der Vergangenheit gezeigt. Nur wenige Daten liegen vor, die über[for full text, please go to the a.m. URL], 61. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie

Einleitung: Eine Helikopterlandung suggeriert im Routinebetrieb eines Zentrumspitals mehr Dringlichkeit als ein eintreffendes Ambulanzfahrzeug. Wir wollten im Rahmen unserer Traumaversorgung wissen, inwieweit sich dies objektivieren lässt bzw. worin sich Verunfallte je nach Transportart unterscheiden.[for full text, please go to the a.m. URL], 132. Kongress der Deutschen Gesellschaft für Chirurgie

Fragestellung: Im Rahmen der hochspezialisierten Medizin sind seit 2012 in der Schweiz nur noch ausgewählte Zentren zur Versorgung von Schwerverletzten zugelassen. Somit ist längerfristig u.a. mit einer Zunahme von Frühverlegungen in diese Zentren zu rechnen. Wir interessierten uns für[for full text, please go to the a.m. URL], Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2014)

Fragestellung: Die effektiv verfügbaren Ressourcen auf unseren Notfallstationen sind angesichts stetig steigender Patientenzahlen bei zugleich bereits ausgelasteten Infrastrukturen bzw. wachsender Personalknappheit zunehmend limitiert. Je länger die Behandlung eines Patienten im Schockraum[for full text, please go to the a.m. URL], Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2013)

Fragestellung: Aktuell gibt es kein ausreichend validiertes Messinstrument zur spezifischen Outcome-Erfassung nach Polytrauma. Ziel dieser Studie war es, das kürzlich entwickelte Trauma Outcome Profile (TOP) im Langzeitverlauf schwerverletzter Patienten zu untersuchen. Methodik: Klinische Te[for full text, please go to the a.m. URL], Deutscher Kongress für Orthopädie und Unfallchirurgie; 75. Jahrestagung der Deutschen Gesellschaft für Unfallchirurgie, 97. Tagung der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie, 52. Tagung des Berufsverbandes der Fachärzte für Orthopädie

Fragestellung: Über die Schmerzen schwer mehrfachverletzter Patienten im Langzeitverlauf nach dem Unfallereignis ist nur wenig bekannt. Wir untersuchten den Schmerzstatus von Überlebenden mind. 2 Jahre nach Polytrauma sowie potentiell erklärende Faktoren in diesem Zusammenhang. Met[for full text, please go to the a.m. URL], Deutscher Kongress für Orthopädie und Unfallchirurgie; 75. Jahrestagung der Deutschen Gesellschaft für Unfallchirurgie, 97. Tagung der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie, 52. Tagung des Berufsverbandes der Fachärzte für Orthopädie

Einleitung: Was geschieht mit einem „geheilten“ polytraumatisierten Patienten (ISS>16) nach Rückkehr in sein häusliches Umfeld? Gibt es Prognosefaktoren, die eine spätere Erwerbsunfähigkeit (longer-term reduced capacity to work (RCW)) vorhersagen? [for full text, please go to the a.m. URL], 128. Kongress der Deutschen Gesellschaft für Chirurgie

The novel thiadiazinone EMD 57033 (EMD) increases the calcium responsiveness of the contractile proteins in cardiac muscle. In skinned ventricular trabeculate isolated from guinea-pig heart, application of 10 μM EMD shifted the curve relating isometric tension to the applied calcium concentration to the left and increased maximal tension by 15%. In intact trabeculae, the rate of heat production, an indicator of the rate of ATP hydrolysis in the steady state, and isometric tension were measured at 37°C. Both the thiadiazinone (EMD; 2.5, 5, and 10 μM) and the cardiac glycoside dihydro-ouabain (DHO; 5, 10, and 20 μM) produced a concentration-dependent increase in contraction-related heart production (H c ) and in the tension time integral of isometric contractions (T d ). In the presence of EMD the energy cost of active tension (H c /T d ) was substantially decreased as compared to control conditions. The energy cost of the positive inotropic effect of EMD (43.8 mW N -1 cm -1 ) was only about half as large as the energy cost of the positive inotropic effect of DHO (88.4 mW N -1 cm -1 ). It is concluded that EMD causes a change in cross-bridge kinetics that increases the contractility of cardiac muscle and improves the economy of chemo-mechanical energy transduction. Our results suggest that EMD 57033 represents a prototype of a new class of cardiotonic agents that might be potentially useful in the therapy of congestive heart failure.

When a person, due to brain injury or another disease, suffers in his or her ability to speak, it becomes inherently cumbersome to share needs, emotions, and experiences through personal stories and social interaction. This paper describes the aim and progress of the author’s dissertation, which focuses on designing a support system to share daily experiences for people suffering from expressive aphasia.

This text presents an evaluation of the activities of the Adolpho Lutz project and a history of tropical medicine in Brazil: progress in the preparation of texts and Lutz's correspondence for publication, the description and treatment of components of his papers, which are found at the National Museum. Appendices include a list of posts, titles, awards and decorations received by Adolpho Lutz, his bibliography and a selection of letters received by him.

A bioassay for salmon prolactin (PRL) is described. This assay which is based on the sodium-retaining action of PRL in the hypophysectomized killifish, Fundulus heteroclitus, has proved to be rapid, sensitive (250 pg PRL per gram of fish), and specific. The procedure has been used to characterize the biological activity of a highly purified PRL from the pituitaries of the chinook salmon, Oncorhynchus tschawytscha, and a similar PRL isolated (by acid buffer polyacrylamide disc gel electrophoresis) from pituitaries of coho salmon (O. kisutch) (MW ca. 22,000; isoelectric point greater than 9).

Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers. (C) 2019 Published by Elsevier B.V. on behalf of European Association of Urology.

Background Since pediatric cancer drug development is a global enterprise, we sought to provide an overview of the landscape of intercontinental clinical trials in pediatric oncology opened over the last decade. Methods ClinicalTrials.gov was systematically searched to identify all clinical therapeutic trials which opened between 2010 and 2020 and recruited pediatric patients (, Intercontinental collaboration is alarmingly rare in childhood cancer trials, despite the rare disease setting and despite pediatric clinical research being inevitably a global enterprise. Barriers to collaboration should be identified and met with specific solutions to accelerate urgently needed drug development for children and adolescents with cancer.

Deferred active treatment (DAT) strategies, including active surveillance and active monitoring, are a recognised management option for men with localised low-risk prostate cancer. However, there is uncertainty due to heterogeneity of patient selection criteria, follow-up and monitoring characteristics, reclassification thresholds, and which outcome measures should be prioritised. This protocol describes a study led by the European Association of Urology (EAU) Prostate Cancer Guidelines Panel in conjunction with other guideline organisations and societies to develop consensus statements for all domains of deferred active treatment. The project is divided into 3 sequential phases: (1) Systematic review of studies reporting on DAT in order to summarise and define range of heterogeneity regarding all domains; (2) Two-round Delphi online survey involving a large, international panel of healthcare professionals (HCPs) and patients to initiate consensus; and (3) Consensus group meeting involving representatives from HCP and patient stakeholder groups to finalise the consensus process. The consensus statements are expected to be adopted by clinical practice guidelines in order to standardise and guide practice for clinicians and researchers until better evidence emerges. Patient summary: We describe a project aimed at standardising elements of practice in active surveillance/monitoring for early localised prostate cancer, because currently there is great variation and uncertainty regarding how best to conduct them. This will be achieved through a structured process of agreement (i.e. consensus) amongst a large, international panel of healthcare professionals and patients.

Purpose: To facilitate the initiation of observational studies on late effects of proton therapy in pediatric patients, we report on current patterns of proton therapy use worldwide in patients aged less than 22 years. Materials & methods: Fifty-four proton centers treating pediatric patients in 2016 in 11 countries were invited to respond to a survey about the number of patients treated during that year by age group, intent of treatment, delivery technique and tumor types. Results: Among the 40 participating centers (participation rate: 74%), a total of 1,860 patients were treated in 2016 (North America: 1205, Europe: 432, Asia: 223). The numbers of patients per center ranged from 1 to 206 (median: 29). Twenty-four percent of the patients were

Great advances have been made in the treatment of paediatric non-Hodgkin lymphoma (NHL). In high-income countries (HIC), cure rates now exceed 85%. However, in low- and middle-income countries (LMIC), cure rates remain less than 50%. It is estimated that over 90% of paediatric NHL worldwide occur in LMIC; therefore, even modest improvements in outcome would have significant impact in reducing the burden of paediatric NHL globally. This article will discuss some of the issues required to improve the outcome of paediatric NHL in LMIC using data presented at the Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma held in Varese, Italy, 2015 to illustrate these issues. Additionally, potential bi-directional benefits for patients in both LMIC and HIC from future collaborations will be discussed.